NCT01497041Unknown2 期
A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment
Korean South West Oncology Group10 个研究点 分布在 2 个国家目标入组 35 人开始时间: 2011年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 35
- 试验地点
- 10
- 主要终点
- Response rate
研究概览
简要总结
- Goals
The primary goal of this phase II trial is to:
evaluate the response rate of combination chemotherapy with docetaxel and oxaliplatin in patients with stage IIIB/IV non-adenocarcinoma, non-small cell lung cancer (NSCLC) as second-line treatment
Secondary goals are to:
evaluate the treatment-related toxicities of this combination, investigate progression-free survival (PFS) and overall survival (OS) in this population 2. Design The proposed clinical trial is an open label, non-comparative, multicenter phase II trial according to the two stage testing design by Simon two-stage testing procedure
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who were diagnosed as non-adenocarcinoma, non-small cell carcinoma of lung histologically or cytologically
- •Patients must be ≥ 18 years old of age
- •ECOG performance status ≤ 1
- •Estimated life expectancy of more than 3 months
- •Treatment with only one prior chemotherapy
- •At least one lesion that can be measured by imaging (CT/MRI) according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
- •Adequate bone marrow function (absolute neutrophil count [ANC] ≥ 1,500/µL, hemoglobin ≥ 9.0 g/dL [correction by transfusion is acceptable], and platelets ≥ 100,000/µL)
- •Adequate kidney function (serum creatinine < 1.5 x upper limit of normal [ULN])
- •Adequate liver function (serum total bilirubin < 1.5xULN; serum transaminases levels < 2.5xUNL)
- •Provision of fully informed consent prior to any study specific procedures
排除标准
- •Pregnant or breastfeeding women and women of childbearing potential not employing adequate contraception
- •Patients who received prior chemotherapy including paclitaxel or docetaxel
- •Patients with second primary cancer (except, adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥5 years)
- •Patients with defect of central nervous system (CNS) or any psychiatric disorders and CNS metastases
- •Other serious illness or medical conditions A. Clinically significant cardiac disease (uncontrolled congestive heart disease despite treatment [NYHA class III or IV], symptomatic coronary artery disease, unstable angina or myocardial infarction, conduction abnormality like grade 2 AV block, serious arrhythmia needed for medication, uncontrolled hypertension) within 6 months prior to study entry B. Liver cirrhosis (≥ Child-Pugh class B) C. History of significant neurologic or psychiatric disorders including dementia or seizures D. Active uncontrolled infection E. Other serious underlying medical conditions which could impair the ability of the patient to participate in the study
- •Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy
结局指标
主要结局
Response rate
时间窗: 2years
Assessment of response will be assessed according to RECIST v1.1 criteria
次要结局
- Overall survival(2years)
- Progression free survival(2 years)
- Number of Participants with Adverse Events(2 years)
- Quality of life(2 years)
研究者
研究点 (10)
Loading locations...
相似试验
Unknown
2 期
Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract CancerBiliary Tract CancerNCT01234051Korean South West Oncology Group53
已完成
1 期
Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate CancerProstate CancerNCT00559429Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins13
终止
2 期
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung CancerNon-small-Cell Lung CarcinomaNCT00232206Providence Health & Services40
已完成
2 期
Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General StatusGastric CancerNCT00733616Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)44
已完成
2 期
Docetaxel+Oxali+/-Cetux Met Gastric/GEJGastric Cancer Adenocarcinoma MetastaticNCT00517829US Oncology Research150